Latest Commercial Execution News

Ramsay Health Care reported a modest 1.7% increase in underlying net profit for FY25, driven by strong Australian and UK hospital performances despite significant impairments in the UK. The company is advancing its multi-year transformation and expects EBIT growth in Australia for FY26, though challenges remain.

AI-Media Technologies has accelerated its transformation into a technology-led business, reporting a 19% increase in technology revenue and launching its AI-powered LEXI Voice product in FY25.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

HMC Digital Infrastructure Ltd’s DigiCo REIT reports FY25 EBITDA ahead of guidance, with its SYD1 data centre achieving ‘Certified Strategic’ status, underpinning expansion plans and senior hires.

DigiCo Infrastructure REIT has reported FY25 results ahead of forecasts, boosted by the SYD1 data centre’s ‘Certified Strategic’ status and robust development progress across Australia and the US.

VHM Limited has appointed Andrew King as CEO and Benjamin McCormick as CFO to spearhead the critical next stage of its Goschen Rare Earths Project development, while outgoing CEO Ron Douglas transitions to a non-executive role.

Memphasys Limited pivots from development to commercial execution with its flagship IVF product Felix, targeting global markets through direct sales and recurring revenue streams.

Atomo Diagnostics has secured a US$410,000 order from Lumos Diagnostics for its Pascal test cassettes, following Lumos's exclusive six-year US distribution deal for the FebriDx test with PHASE Scientific.

Fluence Corporation Limited reported a positive net operating cash flow of US$5.1 million for Q2 2025, boosting its cash reserves to US$12.7 million and maintaining solid liquidity through revolving credit and loan facilities.

Jupiter Mines reports record FY2025 manganese sales and production at Tshipi mine, while Q4 earnings dip due to lower prices and higher costs. Exxaro’s planned majority acquisition signals a new chapter for the asset.